



## PRIOR AUTHORIZATION POLICY

**POLICY:** Oncology (Oral – Androgen Receptor Inhibitor) – Nubeqa Prior Authorization Policy

- Nubeqa® (darolutamide tablets – Bayer)

**REVIEW DATE:** 02/12/2025

### INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

## CIGNA NATIONAL FORMULARY COVERAGE:

### OVERVIEW

Nubeqa, an androgen receptor inhibitor, is indicated for the treatment of adults for the following uses:<sup>1</sup>

- **Prostate cancer, metastatic castration-sensitive.**
- **Prostate cancer, metastatic, castration-sensitive**, in combination with docetaxel.
- **Prostate cancer, non-metastatic, castration-resistant.**

### Guidelines

According to the National Comprehensive Cancer Network guidelines for **prostate cancer** (version 2.2025 – April 16, 2025), for non-metastatic, castration-resistant prostate cancer, androgen deprivation therapy (ADT) is continued to maintain castrate serum levels of testosterone (< 50 ng/dL).<sup>2</sup> Nubeqa, Erleada™ (apalutamide tablets) and Xtandi® (enzalutamide tablets and capsules) are all

category 1 "Preferred" regimens if the prostate specific antigen doubling time is  $\leq$  10 months. For metastatic castration sensitive prostate cancer with high-volume synchronous or metachronous metastases, the guidelines recommend abiraterone, and Nubeqa as category 1 "Preferred" regimens in combination with ADT and docetaxel. Nubeqa is listed under "Other Recommended Regimens" when used in combination with ADT alone (category 2A). For low-volume synchronous or metachronous metastases Nubeqa in combination with ADT, with or without docetaxel, is a category 2B recommendation under "Other Recommended Regimens".

## **POLICY STATEMENT**

Prior Authorization is recommended for prescription benefit coverage of Nubeqa. All approvals are provided for the duration noted below.

• **Nubeqa® (darolutamide tablets - Bayer)**  
**is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):**

## **FDA-Approved Indications**

- 1. Prostate Cancer – Metastatic, Castration-Sensitive.** Approve for 1 year if the patient meets BOTH of the following (A and B):
  - A)** Patient is  $\geq$  18 years of age; AND
  - B)** Patient meets ONE of the following (i or ii):
    - i.** The medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog; OR  
Note: Examples are leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant), Vantas (histrelin acetate subcutaneous implant), Firmagon (degarelix subcutaneous injection), Orgovyx (relugolix tablets).
    - ii.** Patient has had a bilateral orchiectomy.
- 2. Prostate Cancer – Non-Metastatic, Castration-Resistant.** Approve for 1 year if the patient meets BOTH of the following (A and B):
  - A)** Patient is  $\geq$  18 years of age; AND
  - B)** Patient meets ONE of the following (i or ii):
    - i.** The medication is used concurrently with a gonadotropin-releasing hormone (GnRH) analog; OR  
Note: Examples are leuprolide acetate, Lupron Depot (leuprolide acetate intramuscular injection), Trelstar (triptorelin pamoate intramuscular injection), Zoladex (goserelin acetate subcutaneous implant), Vantas

- (histrelin acetate subcutaneous implant), Firmagon (degarelix subcutaneous injection), Orgovyx (relugolix tablets).
- ii. Patient has had a bilateral orchiectomy.

## CONDITIONS NOT COVERED

- **Nubeqa® (darolutamide tablets - Bayer)** is(are) considered not medically necessary for ANY other use(s); criteria will be updated as new published data are available.

## REFERENCES

1. Nubeqa® tablets [prescribing information]. Whippany, NJ: Bayer; June 2025.
2. The NCCN Prostate Cancer Clinical Practice Guidelines in Oncology (version 2.2025 – April 16, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed June 5, 2025.
3. The NCCN Drugs & Biologics Compendium. © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on February 10, 2025. Search term: darolutamide.

## HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	<b>Prostate Cancer – Metastatic, Castration-Sensitive:</b> In reference to docetaxel therapy, added new criteria "Patient has completed docetaxel therapy". Nubeqa is taken concurrently with docetaxel or can also be continued after docetaxel therapy.	07/19/2023
Annual Revision	<b>Prostate Cancer – Metastatic, Castration-Sensitive:</b> The criterion requiring the trial of gonadotropin-releasing hormone "agonist" was changed to "analog", which allows use of both agonists and antagonists. Firmagon and Orgovyx were added as examples in the Note. The separate criterion previously asking for concurrent use of medication with Firmagon was deleted since it is no longer needed. <b>Prostate Cancer – Non-Metastatic, Castration-Resistant:</b> The criterion requiring the trial of gonadotropin-releasing hormone "agonist" was changed to "analog", which allows use of both agonists and antagonists. Firmagon and Orgovyx were added as examples in the Note. The separate criterion previously asking for concurrent use of medication with Firmagon was deleted since it is no longer needed.	08/14/2024
Early Annual Revision	<b>Prostate Cancer – Metastatic, Castration-Sensitive:</b> Deleted criteria referring to concurrent docetaxel therapy or has completed docetaxel therapy based on guideline updates.	02/12/2025
Update	04/17/2025: The policy name was updated from "Oncology – Nubeqa PA Policy" to "Oncology (Oral - Androgen Receptor Inhibitor) – Nubeqa PA Policy".	N/A
Update	06/05/2025: Updated Overview section with new indication for Nubeqa and guidelines.	N/A

N/A – Not applicable.

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group.© 2025 The Cigna Group.